Phase I/II study of SU11248 (Sutent) in combination with metronomic dosing of cyclophosphamide and methotrexate in patients with metastatic breast cancer
Phase of Trial: Phase I/II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Sunitinib (Primary) ; Cyclophosphamide; Methotrexate
- Indications Advanced breast cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Sep 2012 Planned end date changed from 1 Dec 2010 to 1 Dec 2013 as reported by ClinicalTrials.gov.